These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38970214)

  • 1. A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.
    Iaffaldano P; Lucisano G; Guerra T; Paolicelli D; Portaccio E; Inglese M; Foschi M; Patti F; Granella F; Romano S; Cavalla P; De Luca G; Gallo P; Bellantonio P; Gallo A; Montepietra S; Di Sapio A; Vianello M; Quatrale R; Spitaleri D; Clerici R; Torri Clerici V; Cocco E; Brescia Morra V; Marfia GA; Boccia VD; Filippi M; Amato MP; Trojano M;
    Ann Clin Transl Neurol; 2024 Aug; 11(8):2008-2015. PubMed ID: 38970214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
    Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
    JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials.
    Ingwersen J; Masanneck L; Pawlitzki M; Samadzadeh S; Weise M; Aktas O; Meuth SG; Albrecht P
    Sci Rep; 2023 Sep; 13(1):15003. PubMed ID: 37696848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
    Boz C; Ozakbas S; Terzi M; Karabudak R; Sevim S; Turkoglu R; Soysal A; Balcı BP; Efendi H; Turan ÖF; Yüceyar N; Yetkin MF; Karahan SZ; Demirkıran M; Guler S; Agan K; Kıylıoğlu N; Baba C; Tuncer A; Köseoğlu M
    Neurol Sci; 2023 Jun; 44(6):2121-2129. PubMed ID: 36689010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
    Kalincik T; Sharmin S; Roos I; Freedman MS; Atkins H; Burman J; Massey J; Sutton I; Withers B; Macdonell R; Grigg A; Torkildsen Ø; Bo L; Lehmann AK; Havrdova EK; Krasulova E; Trnený M; Kozak T; van der Walt A; Butzkueven H; McCombe P; Skibina O; Lechner-Scott J; Willekens B; Cartechini E; Ozakbas S; Alroughani R; Kuhle J; Patti F; Duquette P; Lugaresi A; Khoury SJ; Slee M; Turkoglu R; Hodgkinson S; John N; Maimone D; Sa MJ; van Pesch V; Gerlach O; Laureys G; Van Hijfte L; Karabudak R; Spitaleri D; Csepany T; Gouider R; Castillo-Triviño T; Taylor B; Sharrack B; Snowden JA; ; ; Mrabet S; Garber J; Sanchez-Menoyo JL; Aguera-Morales E; Blanco Y; Al-Asmi A; Weinstock-Guttman B; Fragoso Y; de Gans K; Kermode A;
    JAMA Neurol; 2023 Jul; 80(7):702-713. PubMed ID: 37437240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
    Roos I; Sharmin S; Malpas C; Ozakbas S; Lechner-Scott J; Hodgkinson S; Alroughani R; Eichau Madueño S; Boz C; van der Walt A; Butzkueven H; Buzzard K; Skibina O; Foschi M; Grand'Maison F; John N; Grammond P; Terzi M; Prévost J; Barnett M; Laureys G; Van Hijfte L; Luis Sanchez-Menoyo J; Blanco Y; Oh J; McCombe P; Ramo Tello C; Soysal A; Prat A; Duquette P; Yamout BI; Khoury S; van Pesch V; Macdonell R; José Sá M; Slee M; Kuhle J; Maimone D; Spitaleri D; Willekens B; Asmi AA; Tallantyre E; Robertson NP; Coles A; L Brown JW; Kalincik T
    Mult Scler; 2024 Aug; 30(9):1163-1175. PubMed ID: 39087208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.
    Alharbi MA; Aldosari F; Althobaiti AH; Abdullah FM; Aljarallah S; Alkhawajah NM; Alanazi M; AlRuthia Y
    BMC Health Serv Res; 2023 May; 23(1):552. PubMed ID: 37237257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
    Smoot K; Marginean H; Gervasi-Follmar T; Chen C; Repovic P; Cohan S
    Mult Scler; 2023 Jul; 29(8):956-966. PubMed ID: 37317841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up.
    Erdogan T; Cansu C; Kocer B; Akkaya S; Kokmen H
    Acta Neurol Belg; 2024 Aug; 124(4):1385-1391. PubMed ID: 38769274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mancinelli CR; Scarpazza C; Cordioli C; De Rossi N; Rasia S; Turrini MV; Capra R
    Mult Scler; 2021 Apr; 27(5):790-794. PubMed ID: 32749910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.
    Simone M; Lucisano G; Guerra T; Paolicelli D; Rocca MA; Brescia Morra V; Patti F; Annovazzi P; Gasperini C; De Luca G; Ferraro D; Margari L; Granella F; Pozzilli C; Romano S; Perini P; Bergamaschi R; Coniglio MG; Lus G; Vianello M; Lugaresi A; Portaccio E; Filippi M; Amato MP; Iaffaldano P;
    J Neurol; 2024 Oct; 271(10):6782-6790. PubMed ID: 39179712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
    Portaccio E; Betti M; De Meo E; Addazio I; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Torri Clerici V; Protti A; Ferraro D; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Comi G; Filippi M; Trojano M; Amato MP;
    J Neurol; 2024 Aug; 271(8):5074-5082. PubMed ID: 38805052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
    Bigaut K; Kremer L; Fabacher T; Ahle G; Goudot M; Fleury M; Gaultier C; Courtois S; Collongues N; de Seze J
    J Neurol; 2022 Jun; 269(6):3295-3300. PubMed ID: 34982200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).
    Chisari CG; Bianco A; Brescia Morra V; Calabrese M; Capone F; Cavalla P; Chiavazza C; Comi C; Danni M; Filippi M; Iaffaldano P; Lanzillo R; Lo Fermo S; Lucisano A; Lugaresi A; Lus G; Marfia GA; Marinelli F; Mirabella M; Moiola L; Perin C; Realmuto S; Toscano S; Trojano M; Vecchio D; Patti F;
    Neurotherapeutics; 2023 Oct; 20(6):1696-1706. PubMed ID: 37610702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
    Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; Rozsa C; Grand'Maison F; Boz C; Granella F; Slee M; Spitaleri D; Olascoaga J; Bergamaschi R; Verheul F; Vucic S; McCombe P; Hodgkinson S; Sanchez-Menoyo JL; Ampapa R; Simo M; Csepany T; Ramo C; Cristiano E; Barnett M; Butzkueven H; Coles A;
    Lancet Neurol; 2017 Apr; 16(4):271-281. PubMed ID: 28209331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.
    Signoriello E; Signori A; Lus G; Romano G; Marfia GA; Landi D; Napoli F; D' Amico E; Zanghí A; Di Filippo PS; Caliendo D; Carotenuto A; Spiezia AL; Fantozzi R; Centonze D; Lucchini M; Mirabella M; Cocco E; Frau J; Maniscalco GT; Di Battista ME; Foschi M; Surcinelli A; Bonavita S; Abbadessa G; Pasquali L; Di Gregorio M; Ferrò MT; Sormani MP; Schiavetti I;
    Mult Scler Relat Disord; 2024 Jul; 87():105594. PubMed ID: 38718748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High NEDA and No PIRA in Natalizumab-Treated Patients With Pediatric-Onset Multiple Sclerosis.
    Puthenparampil M; Gaggiola M; Ponzano M; Zanotelli G; Miscioscia A; Nosadini M; Di Paola A; Sartori S; Perini P; Rinaldi F; Bovis F; Gallo P
    Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200303. PubMed ID: 39141876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.
    Zanghì A; Gallo A; Avolio C; Capuano R; Lucchini M; Petracca M; Bonavita S; Lanzillo R; Ferraro D; Curti E; Buccafusca M; Callari G; Barone S; Pontillo G; Abbadessa G; Di Francescantonio V; Signoriello E; Lus G; Sola P; Granella F; Valentino P; Mirabella M; Patti F; D'Amico E
    Neurotherapeutics; 2021 Apr; 18(2):1166-1174. PubMed ID: 33844155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.